Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 30, 2026

Conditions
HypertriglyceridemiaFamilial Chylomicronemia Syndrome
Interventions
DRUG

RN0361

Placebo

Trial Locations (9)

3004

RECRUITING

Nucleus Network Melbourne, Melbourne

3025

NOT_YET_RECRUITING

Altona Clinical Research, Altona N.

4556

NOT_YET_RECRUITING

University of the Sunshine Coast Clinical Trials, Sippy Downs, Sippy Downs

30047

NOT_YET_RECRUITING

Lifeline Primary Care/Avacare, Lilburn

40383

NOT_YET_RECRUITING

Versailles Family Medicine / Avacare, Versailles

56529

NOT_YET_RECRUITING

Axis Clinicals USA, Dilworth

77598

NOT_YET_RECRUITING

Tranquil, Webster

84404

NOT_YET_RECRUITING

Ogden Clinic, Mountain View / Avacare, Pleasant View

Unknown

NOT_YET_RECRUITING

University of the Sunshine Coast Clinical Trials, Morayfield

Sponsors
All Listed Sponsors
lead

Ikaria Bioscience Pty Ltd

INDUSTRY

NCT06471543 - Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects | Biotech Hunter | Biotech Hunter